-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Cybrexa Therapeutics today announced that preclinical cancer models have demonstrated that the peptide-conjugated drug (PDC) CBX-12 under development can enhance the effectiveness of immune checkpoint inhibitors
Point inhibitors combined with chemotherapy are standard treatments for many solid tumors, but bone marrow suppression associated with chemotherapy can reduce the efficacy of immunotherapy
So, is there any way to specifically target a wide range of tumor types while avoiding toxicity?
One of the characteristics of all tumors is the acidic microenvironment
This selective targeting of tumor cells' mechanism of action avoids the toxicity associated with the therapy's attack on healthy cells
▲The mechanism of using low pH insert peptides to deliver anti-cancer drugs to tumor cells (picture source: Cybrexa official website)
The researchers used a mouse model of colorectal cancer to further evaluate the effect of CBX-12 on the efficacy of PD-1 and CTLA4 immune checkpoint inhibitors
Not only that, but mice that experienced complete tumor regression also showed long-term immune memory
Dr.
Reference materials:
[1] A peptide-drug conjugate that targets the acidic environment of cancer cells may improve the efficacy of immunotherapy.
(The original text has been deleted)